Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Melanoma treatment has advanced, with BRAF inhibitors targeting 50% of melanomas.
• The remaining 50% of melanomas are BRAF wild-type, lacking targeted therapies.
• Approved immune checkpoint inhibitors (PD-1, CTLA4, Lag-3) face challenges in treating BRAF wild-type melanoma post-progression.

Purpose of the Study:

• To review US FDA-approved therapies for BRAF wild-type melanoma.
• To explore developing treatment avenues for BRAF wild-type melanoma patients.
• To discuss novel targeted and immunotherapies for BRAF wild-type melanoma.

Main Methods:

• Review of genomic features in BRAF mutant and wild-type melanoma.
• Analysis of current US FDA-approved therapies for BRAF wild-type melanoma.
• Exploration of emerging targeted therapies within the MAPK pathway.
• Investigation of novel immunotherapies including checkpoint inhibitors, cytokine therapies, oncolytic viruses, and tumor-infiltrating lymphocytes.

Main Results:

• BRAF wild-type melanoma represents a significant therapeutic challenge after initial immune checkpoint blockade.
• The mitogen-activated protein kinase (MAPK) pathway is a focus for new targeted therapies.
• Novel immunotherapies show promise for patients progressing on current treatments.

Conclusions:

• BRAF wild-type melanoma requires further therapeutic development beyond current immune checkpoint inhibitors.
• Targeted therapies and novel immunotherapies offer potential future treatment strategies.
• Continued research into BRAF wild-type melanoma is crucial for improving patient outcomes.